PHARVARIS N V's ticker is PHVS and the CUSIP is N69605108. A total of 22 filers reported holding PHARVARIS N V in Q2 2023. The put-call ratio across all filers is - and the average weighting 3.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $27,743,013 | +37.8% | 1,329,325 | 0.0% | 2.05% | +31.8% |
| Q2 2023 | $20,125,981 | +87.8% | 1,329,325 | 0.0% | 1.56% | +119.9% |
| Q1 2023 | $10,714,360 | -19.8% | 1,329,325 | +12.0% | 0.71% | -15.2% |
| Q4 2022 | $13,357,204 | +185.5% | 1,187,307 | +94.6% | 0.83% | +274.0% |
| Q3 2022 | $4,679,000 | -59.2% | 610,000 | +17.5% | 0.22% | -60.5% |
| Q2 2022 | $11,477,000 | +22.5% | 519,339 | +0.6% | 0.56% | +14.4% |
| Q1 2022 | $9,366,000 | +26.1% | 516,321 | 0.0% | 0.49% | +40.3% |
| Q4 2021 | $7,430,000 | +0.0% | 516,321 | +23.2% | 0.35% | -8.3% |
| Q3 2021 | $7,428,000 | +258.7% | 418,943 | +276.9% | 0.38% | +317.4% |
| Q2 2021 | $2,071,000 | +48.0% | 111,144 | +122.3% | 0.09% | +58.6% |
| Q1 2021 | $1,399,000 | – | 50,000 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 3,743,450 | $56,675,833 | 27.86% |
| venBio Partners LLC | 4,264,672 | $64,567,134 | 23.37% |
| Bain Capital Life Sciences Investors, LLC | 4,868,784 | $73,713,390 | 7.59% |
| VR Adviser, LLC | 1,326,200 | $20,078,668 | 3.21% |
| 5AM Venture Management, LLC | 587,600 | $8,896,264 | 2.22% |
| Novo Holdings A/S | 1,329,325 | $20,125,981 | 1.56% |
| GENERAL ATLANTIC, L.P. | 4,406,252 | $66,710,655 | 1.05% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 200,000 | $3,028,000 | 0.94% |
| Cormorant Asset Management, LP | 973,614 | $14,740,516 | 0.83% |
| Soleus Capital Management, L.P. | 391,900 | $5,933,366 | 0.66% |